Patents Assigned to Shire-NPS Pharmaceuticals, Inc.
  • PARATHYROID HORMONE VARIANTS
    Publication number: 20200247865
    Abstract: The invention relates to parathyroid hormone (PTH) variants and pharmaceutical compositions comprising same. The invention further relates to PTH compositions with improved serum half-life and peak-trough ratios, and methods of controlling serum calcium levels with the PTH variants and compositions of the invention. The invention further relates to methods of treating hypoparathyroidism and/or hypocalcemia due to hypoparathyroidism with the PTH variants and compositions of the invention.
    Type: Application
    Filed: January 29, 2020
    Publication date: August 6, 2020
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Clark PAN, Angela NORTON, Kevin HOLMES, David Bruce LLOYD, Bryan James GOODWIN, Rongxin SHI, Sujit JAIN, Chuan SHEN
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200206316
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: March 11, 2020
    Publication date: July 2, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • GLP-2 FUSION POLYPEPTIDES AND USES FOR TREATING AND PREVENTING GASTROINTESTINAL CONDITIONS
    Publication number: 20200199192
    Abstract: Described are fusion proteins of GLP-2 with an Fc region of immunoglobulin. The GLP-2 and Fc regions are separated by a linker comprised of amino acids. The fusion proteins persist and remain active in the body for longer periods of time than GLP-2 itself. Methods are disclosed of using the fusion proteins to treat and prevent enterocutaneous fistulae, radiation damage to the gastrointestinal tract, obstructive jaundice, and short bowel syndrome.
    Type: Application
    Filed: August 21, 2018
    Publication date: June 25, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Clark PAN, Angela NORTON, Bettina STRACK-LOGUE, Kefeng SUN
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200164040
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 28, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200164041
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 28, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200164043
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200147182
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 2, 2020
    Publication date: May 14, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200147181
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: December 23, 2019
    Publication date: May 14, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200138910
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 6, 2020
    Publication date: May 7, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200129593
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: December 27, 2019
    Publication date: April 30, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200129594
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: January 2, 2020
    Publication date: April 30, 2020
    Applicant: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200121761
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: December 20, 2019
    Publication date: April 23, 2020
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20200016241
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: September 12, 2019
    Publication date: January 16, 2020
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190381146
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 19, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • Treatment of Short Bowel Syndrome Patients with Colon-in-Continuity
    Publication number: 20190351027
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: July 30, 2019
    Publication date: November 21, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190307852
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: May 21, 2019
    Publication date: October 10, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190298807
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 3, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190298806
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 3, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190275111
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: May 14, 2019
    Publication date: September 12, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20190275112
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. Blosch